28 Stocks Moving In Friday's Mid-Day Session



  • ChemoCentryx, Inc. CCXI shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis).
  • Renren Inc. RENN jumped 40.9% to $23.40. Renren, last month, named Chris Palmer as its Chief Financial Officer.
  • ReShape Lifesciences Inc. RSLS shares climbed 28.2% to $3.18. Maxim Group initiated coverage on Reshape Lifesciences with a Buy rating and announced a price target of $8.
  • Camber Energy, Inc.. CEI jumped 26.5% to $2.2510 after jumping around 96% on Thursday.
  • Huadi International Group Co., Ltd. HUDI gained 17.7% to $3.73.
  • Altisource Portfolio Solutions S.A. ASPS surged 16.6% to $13.70. The company recently agreed to sell Pointillist subsidiary for $150 million.
  • Aehr Test Systems AEHR gained 14.4% to $19.05. Craig-Hallum raised the price target on Aehr Test Systems to $31 from $12, implying an 86.1% upside, and reiterated a Buy.
  • Repare Therapeutics Inc. RPTX jumped 13.5% to $24.85. Repare Therapeutics issued statement regarding inadvertent issuance of Phase 1/2 TRESR RP-3500 clinical trial abstract by AACR-NCI-EORTC Virtual International Conference.
  • DatChat, Inc. DATS shares rose 11.4% to $8.96 after gaining over 9% on Thursday.
  • Cue Health Inc. HLTH gained 9.4% to $11.82.
  • Momentive Global Inc. MNTV rose 9.3% to $23.64. Momentive Global is weighing options, including a potential sale after receiving takeover interest, Bloomberg reported.
  • eFFECTOR Therapeutics, Inc. EFTR rose 9.1% to $12.52 after the company, in collaboration with investigators at Baylor College of Medicine, announced the presentation of new data for zotatifin in animal models of triple-negative breast cancer at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • Sundial Growers Inc. SNDL rose 8% to $0.70 after the company announced plans to acquire Alcanna for total consideration of approximately $346 million.
  • Immuron Limited IMRN rose 5.7% to $3.72 as the company announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials.

Check out these big penny stock gainers and losers


  • Macquarie Infrastructure Corporation MIC shares fell 91.1% to $3.58 .
  • Allogene Therapeutics, Inc. ALLO shares dipped 43.3% to $13.79 after the company reported the FDA placed a hold on the company's AlloCAR T clinical trials.
  • Agile Therapeutics, Inc. AGRX shares fell 29.5% to $0.6645 after the company announced an offering of common stock and warrants.
  • Cellectis S.A. CLLS fell 19% to $9.74. Baird downgraded Cellectis from Outperform to Neutral and lowered the price target from $39 to $10.
  • Nkarta, Inc. NKTX dipped 13.7% to $21.57. Nkarta updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.
  • Caribou Biosciences, Inc. CRBU dropped 11.7% to $19.95.
  • Blue Apron Holdings, Inc. APRN fell 10% to $7.08.
  • Omeros Corporation OMER dropped 9.9% to $6.70. JP Morgan downgraded Omeros from Neutral to Underweight.
  • Cidara Therapeutics, Inc. CDTX fell 9.6% to $1.69 after the company priced 14.8 million share offering at $1.55 per share.
  • Kiromic BioPharma, Inc. KRBP dropped 9.2% to $1.97. Kiromic BioPharma recently named Daniel Clark as interim Chief Financial Officer.
  • MaxCyte, Inc. MXCT fell 8.4% to $9.81.
  • Sharecare, Inc. SHCR dipped 7.7% to $7.68.
  • Lucira Health, Inc. LHDX dipped 7.6% to $6.10. Lucira Health issued a statement on recall of FLOQSwabs by its Italian partner, Copan Italia.
  • CareMax, Inc. CMAX dropped 7.2% to $8.18.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading IdeasHealth CareHealth Care TechnologyMid-Day MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!